Lu-177 DOTANOC therapy is a targeted radionuclide treatment used primarily for selected somatostatin receptor-positive neuroendocrine tumors (NETs). It combines DOTANOC, which targets somatostatin receptors on tumor cells, with Lutetium-177, a radioactive isotope that delivers radiation directly to receptor-positive cancer cells.
Who May Benefit?
This treatment may be considered for patients with suitable neuroendocrine tumors, particularly when disease is advanced, recurrent, or requires targeted radionuclide therapy. Eligibility depends on factors such as tumor type, receptor expression, disease extent, previous treatments, kidney function, blood counts, and overall health. A specialist evaluation and appropriate imaging, such as a somatostatin receptor scan or PET/CT, are generally required before treatment.
How Is the Treatment Given?
Lu-177 DOTANOC is administered intravenously in a specialized nuclear medicine setting. Patients may receive kidney-protective amino acid infusions and supportive medicines as part of the treatment protocol. The radioactive therapy is monitored carefully by the medical team, with radiation-safety instructions provided before discharge.
Safety and Follow-Up
Possible side effects can include nausea, fatigue, temporary changes in blood counts, and effects on kidney or liver function. Long-term monitoring may be recommended. Your nuclear medicine and oncology team will explain expected benefits, risks, preparation, radiation precautions, and follow-up based on your individual condition.